Jonas S. Møller contributes to PharmaVOICE '2021 Year in Preview'

Acknowledging the "tumultuous year" 2020 has proven to be, PharmaVOICE recently pulled together an interesting review piece, featuring input from several industry experts such as Albumedix CEO; Jonas S. Møller.

Recognizing the positives taken from the year as well as the apparent negatives, the article collates thoughts from a range of contributors, each describing the medical innovations they have been monitoring or contributing to throughout 2020. Thought leaders also shared insights into the trends they'll be keeping an eye on as we move into 2021. 

Regarding Albumedix, Jonas had the following to say:

"This year, the biggest impact on our industry has obviously been the COVID-19 pandemic. As we are supplying customers developing diagnostics, medical devices, and vaccines in the fight against the coronavirus, we are vigilantly watching these developments. Solving challenges in cold-chain storage and transportation are central issues, important in both ensuring COVID-19 vaccines reach patients worldwide, but also an issue advanced therapy developers are addressing to make therapies scalable. Examples here include stability of mRNA vaccines requiring -80°C storage, as well as an increasing trend toward ‘thaw and inject’ of cellular therapies."

Access the full PharmaVOICE article here.